Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 1999

View Archived Issues

Parathyroid hormone prolongs the survival of osteoblasts

Additional U.S. patents will issue for Cortex's Ampakines

SangStat's cold storage solution for donor hearts cleared by FDA

Cubist expands collaboration with Merck & Co.

Ribozyme acquires ribozyme assets from Innovir

FDA approves Cleocin vaginal ovules for treatment of bacterial vaginosis

Ciba Vision and QLT PhotoTherapeutics seek approval for Visudyne in U.S., Switzerland

Titan makes significant progress during Q2 1999

Cangene cancels current offer to acquire Hyal

New company to focus on treatments for Alzheimer's disease

Remicade receives E.U. approval for Crohn's disease treatment

Tularik describes agents for lipoprotein disorders acting via a novel mechanism

Neuronal calcium channel blockers in the pipeline at Toyama

Shionogi synthesizes potent 5-HT7 receptor ligands for CNS, CV disorders

Fuji Pharmaceutical describes therapeutic activity of dual MMP/TACE inhibitors

Merck invention centers on GABA-A receptor ligands for epilepsy, anxiety

Novel uricosuric agents claimed by Yamasa Shoyu

Sucrose-formulated rFVIII: a safe and effective second-generation factor VIII developed by Bayer

In vitro interactions of novel platelet substitute Synthocytes with platelets

Fibrinogen antagonist gantofiban is a promising treatment for peripheral arterial occlusion

FDA approves Organon's short-acting neuromuscular blocker Raplon

P2T antagonist shows antithrombotic effects in blood from patients with unstable angina

Aronex expands Atragen phase II clinical trial in prostate cancer

Axonyx: Q2 1999 highlights

SanOrg-34006, a promising new antithrombotic, is safe for use in the elderly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...